High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma
High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma
复制标题
瘤周肝组织中巨噬细胞集落刺激因子的高表达与肝细胞癌根治性切除后生存率低相关
DOI:
10.1200/jco.2007.15.6521
复制
发表时间:
2008-06-01
影响因子:
45.3
通讯作者:
Sun, Hui-Chuan
中科院分区:
文献类型:
--
作者:
Zhu, Xiao-Dong;Zhang, Ju-Bo;Sun, Hui-Chuan
PurposeTo investigate prognostic values of the intratumoral and peritumoral expression of macrophage colony-stimulating factors (M-CSF) in hepatocellular carcinoma (HCC) patients after curative resection.Patients and MethodsExpression of M-CSF and density of macrophages ( M Phi) were assessed by immunohistochemistry in tissue microarrays containing paired tumor and peritumoral liver tissue from 105 patients who had undergone hepatectomy for histologically proven HCC. Prognostic value of these and other clinicopathologic factors was evaluated.ResultsNeither intratumoral M-CSF nor M Phi density was associated with overall survival ( OS) or disease-free survival (DFS). High peritumoral M-CSF and M Phi density, which correlated with large tumor size, presence of intrahepatic metastasis, and high TNM stage, were independent prognostic factors for both OS ( P =.001 and P =.001, respectively) and DFS ( P =.001 and P =.003, respectively) and affected incidence of early recurrence. In a small HCC subset, peritumoral M-CSF was also correlated with both OS and DFS ( P =.038 and P =.001, respectively). The combination of peritumoral M-CSF and M Phi had a better power to predict the patients' death and disease recurrence ( P =.001 for both).ConclusionHigh peritumoral M-CSF and M Phi were associated with HCC progression, disease recurrence, and poor survival after hepatectomy, highlighting the importance of peritumoral tissue in the recurrence and metastasis of HCC. M-CSF and M Phi may be targets of postoperative adjuvant therapy.